Mason Tootell, MD
Family Medicine · Warren, PANPI 1568675270
Payments from drug & device makers
Across 441 payments — averaging $14.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$829
- AstraZeneca$752
- Boehringer Ingelheim$549
- Lilly USA, LLC$453
- GSK$446
- Merck$363
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,430100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 78 | $829 |
| AstraZeneca | 49 | $752 |
| Boehringer Ingelheim | 40 | $549 |
| Lilly USA, LLC | 33 | $453 |
| GSK | 40 | $446 |
| Merck | 24 | $363 |
| Novo Nordisk | 25 | $359 |
| Bayer | 13 | $321 |
| Amarin Pharma, Inc. | 21 | $316 |
| Johnson & Johnson | 20 | $231 |
| Boston Scientific | 4 | $204 |
| AbbVie | 10 | $167 |
| Amgen | 11 | $163 |
| E.r. Squibb & Sons, L.L.C. | 11 | $157 |
| Exact Sciences | 7 | $142 |
| Astellas Pharma US Inc | 7 | $99 |
| Sunovion Pharmaceuticals Inc. | 4 | $84 |
| Abbott | 4 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $75 |
| Sanofi-aventis U.S. LLC | 4 | $63 |
| Biohaven Pharmaceuticals, Inc. | 4 | $60 |
| Collegium Pharmaceutical, Inc. | 4 | $59 |
| Radius Health, Inc. | 2 | $55 |
| KCI USA, Inc. | 1 | $52 |
| Grifols USA, LLC | 3 | $49 |
| Phathom Pharmaceuticals, Inc. | 3 | $43 |
| Verona Pharma, Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Nestle Healthcare Nutrition Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Almatica Pharma LLC | 1 | $21 |
| Alkermes, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $21 |
| Novartis | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$144
- Kerendia$126
How this compares
$6,435 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 142 | $152,072 |
| MounjaroTirzepatide | 133 | $150,299 |
| EliquisApixaban | 214 | $145,699 |
| FarxigaDapagliflozin Propanediol | 137 | $105,476 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 115 | $73,322 |
| OzempicSemaglutide | 78 | $72,598 |
| XareltoRivaroxaban | 71 | $68,333 |
| NuplazidPimavanserin Tartrate | 12 | $58,621 |
| JardianceEmpagliflozin | 71 | $49,722 |
| Xtampza ErOxycodone Myristate | 52 | $39,622 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 52 | $34,535 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 53 | $30,254 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $24,586 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 38 | $23,673 |
| VivitrolNaltrexone Microspheres | 12 | $19,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $453 | $302,371275 claims |
| PfizerEliquis | $829 | $145,699214 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $446 | $135,478246 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $752 | $111,875148 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $549 | $96,130147 claims |
| Novo NordiskOzempic | $359 | $72,59878 claims |
| Johnson & JohnsonXarelto | $231 | $68,33371 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $59 | $39,62252 claims |
| Alkermes, Inc.Vivitrol | $21 | $19,74712 claims |
| MerckJanuvia | $363 | $17,99015 claims |
| AbbVieRestasis | $167 | $11,27618 claims |
| NovartisEntresto | $18 | $9,80213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Warren
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.